Our approach to clinical development is deeply rooted in our understanding of activin biology and where we believe bimagrumab will have the greatest benefit. Our initial treatment areas are obesity and heart failure with additional indications to follow.
Indication
Preclinical
Phase 1
Phase 2A
Phase 2B
Expansion Opportunities
Adult Obesity
Preclinical
Phase 1
Phase 2A
Phase 2B
Pediatric Obesity
Sarcopenic Obesity
Expansion Opportunities
Pediatric Obesity
Sarcopenic Obesity
Heart Failure in Obesity
Preclinical
Phase 1
Phase 2A
Phase 2B
HFpEF1
HFrEF2
Expansion Opportunities
HFpEF1
HFrEF2
Additional Indications
(undisclosed)
Preclinical
Phase 1
Phase 2A
Phase 2B
1 Heart failure with preserved ejection fraction
2 Heart failure with reduced ejection fraction
Clinical Studies
Bimagrumab has been evaluated in 20+ clinical trials